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Abstract
Although a variety of genetic strategies have been developed to inhibit HIV replication, few direct comparisons of the
efficacy of these inhibitors have been carried out. Moreover, most studies have not examined whether genetic inhibitors are
able to induce a survival advantage that results in an expansion of genetically-modified cells following HIV infection. We
evaluated the efficacy of three leading genetic strategies to inhibit HIV replication: 1) an HIV-1 tat/rev-specific small hairpin
(sh) RNA; 2) an RNA antisense gene specific for the HIV-1 envelope; and 3) a viral entry inhibitor, maC46. In stably transduced
cell lines selected such that .95% of cells expressed the genetic inhibitor, the RNA antisense envelope and viral entry
inhibitor maC46 provided the strongest inhibition of HIV-1 replication. However, when mixed populations of transduced
and untransduced cells were challenged with HIV-1, the maC46 fusion inhibitor resulted in highly efficient positive selection
of transduced cells, an effect that was evident even in mixed populations containing as few as 1% maC46-expressing cells.
The selective advantage of the maC46 fusion inhibitor was also observed in HIV-1-infected cultures of primary T
lymphocytes as well as in HIV-1-infected humanized mice. These results demonstrate robust inhibition of HIV replication
with the fusion inhibitor maC46 and the antisense Env inhibitor, and importantly, a survival advantage of cells expressing
the maC46 fusion inhibitor both in vitro and in vivo. Evaluation of the ability of genetic inhibitors of HIV-1 replication to
confer a survival advantage on genetically-modified cells provides unique information not provided by standard techniques
that may be important in the in vivo efficacy of these genes.
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Introduction
Even though highly active antiretroviral therapy (HAART) has
been remarkably successful in lowering the viral load in patients
with HIV-infection [1], an increasing prevalence of resistant
viruses [2], HAART failure [3], and a significant incidence of
serious side effects [4] have provided the impetus to develop
complementary therapies using genetic inhibitors of HIV-1
replication. With increased understanding of the molecular basis
for HIV replication, a diverse range of genetic strategies able to
inhibit HIV-1 replication in vitro has emerged. These genetic
strategies include RNA inhibitors (i.e., ribozymes, decoys, small
inhibitory RNAs, and antisense molecules), protein-based inhib-
itors (i.e., intracellular antibodies or dominant negative inhibitors),
as well as zinc-finger nucleases that knockout host genes critical for
HIV replication [5–8]. Although many genetic inhibitors have
been demonstrated to mediate potent inhibition of HIV-1
replication [9–12], inhibition of viral replication has generally
been evaluated using in vitro conditions in which .95% of cells
express the inhibitor under study, a highly artificial setting given
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modified CD4
+ T cells in vivo.
A number of different criteria have been proposed for the
selection of genetic inhibitors for advancement to human clinical
trials, including potency of inhibition, lack of immunogenicity, lack
of toxicity, and the propensity for evolution of resistant viruses
[5,6]. An additional, and perhaps underappreciated, criterion is
the stage of the viral life cycle at which inhibition occurs.
Inhibition of viral gene expression by inhibitors that block later
stages of the viral life cycle (e.g. by blocking the function of viral
proteins such as Tat or Rev) will not prevent transduced cells from
becoming infected, while inhibitors that block early events in the
viral life cycle prior to integration can prevent infection.
Mathematical modeling has predicted that post-integration
inhibitors support the accumulation of cells carrying an integrated
provirus, ultimately resulting in an accumulation of HIV-1-
infected cells that counteracts the antiviral effect [13]. In contrast,
early inhibitors, even those with lower potency, are predicted to
exert a systemic antiviral effect and to be able to mediate
expansion of transduced cells able to resist HIV infection.
Translation of genetic inhibitors of HIV-1 replication into
successful therapies has been limited by the disappointing rates of
gene transfer to hematopoieticcells and by the relatively low rates of
genetically-modified T cells that have been achieved in vivo. For
adoptive T cell transfer studies of genetic inhibitors of HIV-1
infection, although in vitro transduction efficiencies resulting in more
than 1 vector copy per cell have been obtained [14], after infusion
into patients, the frequency of vector-containing CD4
+ T cells in vivo
has generally been in the range of 0.01% to 1% [14–18]. For trials
of hematopoietic stem cell gene therapy for AIDS, levels of gene
marking in CD4
+ T cells in vivo after transduction with
gammaretroviral vectors have been disappointingly low, typically
0.01%orless[19,20].Attheselowlevelsofgenemarking,inhibition
of HIV-1 replication in the small fraction of cells containing an
inhibitorygene is unlikely to have a significantimpacton eitherviral
replication or immune reconstitution. However, if cells that contain
a genetic inhibitor are able to proliferate and survive preferentially
compared with unmodified cells, a vastly different scenario
emerges—a progressive repopulation of the immune system with
cells genetically resistant to HIV infection. A compelling proof-of-
principle demonstration of this approach lies in the report of a
successful transplant of an HIV-1-infected individual with bone
marrow from a donor with a mutation in the HIV-1 coreceptor
CCR5, which resulted in a repopulation of peripheral CD4
+ T cells
with donor cells resistant to HIV-1 infection, thereby allowing the
discontinuation of antiretroviraltherapy without viralrebound [21].
However, given the relatively low prevalence of bone marrow
donors who are homozygous for the D32 CCR5 deletion (,1% in
Caucasian populations) [22] as well as the risks associated with
allogeneic bone marrow transplantation, there is a compelling need
for alternative strategies to induce resistance of hematopoietic cells
to HIV-1 infection.
Here, we compared three HIV-specific inhibitor genes for their
potency of viral inhibition and for their ability to confer a selective
advantage following HIV-1 infection in vitro and in vivo. The
membrane-anchored C46 peptide (maC46) [9,23], which blocks
viral fusion and entry, provided the strongest inhibition of viral
replication and, importantly, a strong selective advantage for
transduced cells, both in vitro and in immunodeficient mice
transplanted with human T cells. In contrast, a long RNA
antisense sequence targeting the HIV-1 envelope gene provided
very strong inhibition of viral replication, but transduced cells did
not exhibit a strong survival advantage in vitro. A short hairpin (sh)
RNA inhibitor targeting the HIV-1 tat and rev genes provided
modest inhibition of viral replication, coupled with an inconsistent
selective advantage. Inhibitors of HIV-1 replication able to confer
a survival advantage may have distinct advantages for clinical use,
and these data advocate for the continued development of the
maC46 peptide inhibitor as a genetic therapy strategy for AIDS.
Results
Genetic inhibitors of HIV-1 replication
We directly compared the potency of viral inhibition and the
selective advantage of several lentiviral vectors expressing genetic
inhibitors of HIV-1 replication: 1. HIV-shI-GFP, which contains
the U6 promoter expressing a shRNA targeting exon 1 of HIV-1
tat and rev, as well as GFP expressed by an internal CMV promoter
[11]; 2. M589, which contains an internal SFFV promoter
expressing a membrane-anchored fusion protein (maC46) consist-
ing of the N-terminal C46 heptad repeat from HIV-1 gp41
anchored with a linker and a transmembrane domain fused to
GFP at the intracellular C-terminus [9,23]; and 3) VRX494,
which contains 937 bp of an RNA antisense HIV-1 envelope
sequence and GFP transcriptionally regulated by the HIV-1 LTR
[12] (Figure 1). The lentiviral vectors HJ57 and M420, which do
not contain inhibitor genes but do express GFP, were included as
controls. These genetic inhibitors were selected based on previous
reports demonstrating their efficacy in inhibiting HIV-1 replica-
tion [9,11,12], their ability to target distinct sites in the retroviral
life cycle, including viral entry (maC46) and as well as post-
integration events (shI, VRX494), and their use, either alone
[14,18] or in combination with other genetic inhibitors [24] in
human clinical trials.
The fusion inhibitor maC46 and antisense env VRX494
mediate potent inhibition of HIV-1 replication in
transduced cells
To evaluate inhibition of HIV-1 replication by these three
genetic inhibitors, we transduced a CD4
+ cell line (CEMx174)
with the HIV-shI-GFP, VRX494, or M589 vectors. Transduced
cells were then sorted for expression of GFP, resulting in .95%
GFP
+ cells (data not shown). Sorted transduced T cells were then
challenged with HIV-1NL4-3 at multiple MOIs. As shown in
Figure 2, control T cells, either untransduced or transduced with a
lentivirus expressing GFP alone, supported vigorous HIV-1
replication, with peak HIV-1 p24 antigen production exceeding
1000 ng/ml. In contrast, cells transduced with the VRX494
antisense vector or the M589 vector expressing the maC46 fusion
inhibitor demonstrated quite potent inhibition of viral replication,
ranging between 3 and 4 logs of inhibition compared with control
cells, even at the highest MOI studied. A similar degree of
inhibition mediated by these vectors was observed at MOIs of
10
24 and 10
23 TCID50 per cell, but at 10
22 TCID50 per cell, the
highest MOI studied, maC46-expressing cells demonstrated more
potent inhibition of HIV-1 replication than cells expressing the
VRX494 antisense sequence. These results demonstrate that the
membrane-anchored C46 peptide, which blocks fusion of viral
particles to the cell membrane, and the antisense expressing vector
VRX494 provide stronger inhibition of HIV-1NL4-3 replication
than the shRNA inhibitor, a difference that was particularly
evident following challenge with relatively high MOIs.
Selective expansion of maC46-transduced cells following
HIV-1 infection
To assess the potential for the different vectors to protect
transduced cells from viral cytotoxicity and therefore to provide for
Genetic Inhibitors of HIV
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ducedCD4
+Tcellsweremixedsuchthat approximately25%ofthe
cells were GFP
+. These mixtures remained uninfected or were
infected with HIV-1NL4-3 at an MOI of 10
23 TCID50 per cell and
then followed for expression of HIV-1 p24 Gag and GFP by flow
cytometry. Representative flow cytometry data are shown in
Figure 3A for a mixture of transduced and untransduced cells.
On day 5 after infection, the percentage of maC46-GFP-expressing
cells was essentiallyunchanged from day0,andonlya small fraction
of HIV-1 p24 cells were observed (Figures 3A and 3B). Four days
lateronday9,more than 90% ofthe cellsstainedpositiveforHIV-1
p24 Gag and the percentage of maC46-GFP
+ cells increased from
under 30% to over 85% (Figure 3A and B). The forward/side
scatter plots on day 9 showed many cells with increased granularity
and decreased size characteristic of dead or dying cells, consistent
with the strong cytopathicity of HIV-1 replication in vitro (data not
shown). After 14 days, the non-transduced T cells were almost
completely depleted, with only 1% of the GFP
— cells remaining
(Figure 3A and B). Coincidently, the staining of HIV-1 p24 Gag in
the GFP
+ population also decreased to 28% (Figure 3A). By day 21
of the infection, only a few GFP
— cells could be detected (0.5%) and
the HIV-1 p24 Gag staining in the GFP
+ population decreased to
9%. Although a dramatic increase in the frequency of maC46-GFP-
expressing cells was observed, no significant expansion of cells
expressing the VRX494 antisense envelope or the shRNA inhibitor
was observed (Figure 3B).
Figure 1. Schematic diagrams of the viral transfer plasmids. The lentiviral vectors HIV-shI-GFP, VRX494, M589, HJ57, and M420, are based on
HIV-1NL4-3 or HIV-1HXB2. The viral inhibitors encoded by each of the experimental vectors are noted in parentheses. Where indicated, vectors use a
heterologous CMV promoter to initiate transcription of the genomic RNA with a self-inactivating 39 LTR. The VRX494 vector uses a functional HIV-1
LTR, which is upregulated after viral infection [36]. All vectors contain cis-acting regulatory domains (the y packaging signal, the central polypurine
tract [cppt], the Rev response element [RRE], and, in some cases, the Woodchuck post-transcriptional regulatory element [wPRE]), and eGFP. The
vector HIV-shI-GFP contains the U6 promoter regulating a shRNA targeting exon 1 of HIV-1 tat and rev (shI) [10]. The lentiviral vector VRX494 contains
937 bp of antisense (AS) HIV-1 envelope, and eGFP transcriptionally regulated by the HIV-1 LTR [32]. The vector M589 contains an internal SFFV
promoter regulating expression of the C46 heptad repeat-anchored with a linker and transmembrane domain:GFP fusion protein (maC46:GFP). The
control vectors HJ57 and M420 do not contain an inhibitor cassette.
doi:10.1371/journal.pone.0012357.g001
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animal models and in human clinical trials, we wished to explore
the ability of these vectors to mediate a selective advantage when
present at clinically relevant levels of gene marking. Therefore,
mixtures of untransduced and vector-transduced T cells were
generated, ranging from 1% to 60% GFP
+ cells. Unmixed vector-
transduced populations (.95% GFP
+) were also included. These
mixtures were infected with HIV-1 at an MOI of 10
23 TCID50
per cell or remained uninfected and were then followed for
expression of GFP by flow cytometry (Figure 3C). As demonstrat-
ed previously in Figure 3B, cells expressing the shRNA inhibitor
were not strongly selected for during HIV-1 replication, as the
percent of GFP
+ cells remained constant or only modestly
increased compared to the day 0 frequencies (Figure 3C).
Consistent with a previous study [25], cells expressing the
antisense envelope inhibitor also demonstrated a slight increase
in the percentage of transduced cells during the 25 day observation
period, an effect that was most evident for the cultures containing
25% and 60% transduced cells, while no clear selective advantage
was evident for the cultures containing 1% or 10% transduced
cells. In sharp contrast, the percentage of maC46-expressing cells
increased substantially in all mixed populations, even from a
culture containing only 1% transduced cells at day 0 (Figure 3C).
In the absence of HIV-1 infection, the percentage of transduced
cells expressing a given transgene was relatively stable (data not
shown). Thus, expression of the membrane-anchored fusion
inhibitor resulted in a strong survival advantage following HIV-1
challenge in vitro.
maC46-expressing cells trap HIV-1 virions at the cell
surface without efficient transfer to neighboring cells
Interestingly, even though the cells expressing the membrane-
anchored C46 were able to mediate potent inhibition of viral
replication, they also stained positive for HIV-1 p24 Gag, at least
during the phase where the peak of viral replication occurred in
the non-transduced cells (Figure 3A). To study if this double
positive population was productively infected, we performed
confocal microscopy of a mixed culture of cells expressing
maC46 with untransduced cells after HIV-1 infection. As seen
in Figure 4A, GFP
+ cells expressing maC46 sequestered HIV-1
p24 antigen (red) on the cell surface but did not contain any
intracellular viral antigen. In contrast, GFP
— p24
+ cells contained
large amounts of intracellular p24, indicating virus replication. We
then asked whether virus sequestered on the surface of maC46-
expressing cells was still infectious and could be transmitted to
non-protected, maC46-negative cells. Such a cell-to-cell transmis-
sion could potentially enhance infection of untransduced cells,
thereby accelerating virus spread in the non-protected population
and the relative accumulation of the gene-protected cells in the
mixed culture. Two experiments were performed to test for
Figure 2. Potent inhibition of HIV-1 replication by the maC46 fusion inhibitor and antisense-Env VRX494 vectors. Non-transduced
CEMx174 cells (NT) and CEMx174 cells transduced with vectors expressing the indicated inhibitor gene or a control vector (HJ57, GFP) were infected
with HIV-1NL4-3 at MOIs of (A) 10
24, (B) 10
23, and (C) 10
22 TCID50 per cell. Viral replication was assessed by measuring HIV-1 Gag p24 antigen in cell-
free culture supernatants. The minimum level of detection for HIV-1 Gag p24 was 15 pg/ml. The data are representative of at least two experiments.
doi:10.1371/journal.pone.0012357.g002
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expressing maC46 were incubated for 5 h at 37uC with high
concentrations of a replication-deficient HIV-1 vector expressing
GFP and packaged with an HIV-1 envelope (strain JR-FL). As
expected, cells expressing maC46 trapped the virions on the cell
surface and became clearly p24-positive as detected by FACS,
while only little p24 was detected on non-transduced cells
(Figure 4B). The cells were then washed and mixed with RFP-
expressing PM-1 indicator cells and analyzed for virus transfer
from the A3-CCR5 population to the RFP-positive indicator cell
line PM-1. As a control, HIV-1 vector preparations were directly
transferred to PM-1. The HIV-1/GFP vector was transferred from
both the maC46-expressing and the non-modified A3-CCR5 cells,
resulting in around 5% transduction of the PM-1 population
(Figure 4C). However, taking into account the fact that the
maC46-expressing cells trap far more HIV-1 on the cell surface
than unmodified cells (as seen in Figure 4B), this observation
suggests that the transfer of virus adsorbed to maC46-expressing
cells is highly inefficient. Similar results were observed if the HIV-
1 vector was incubated for only one hour with the A3-CCR5 cells
before washing and mixing with PM-1 (data not shown).
In addition, we followed HIV-1 replication by monitoring p24
antigen in the supernatants of untransduced cells, either alone or
mixed with 10%, 20% and 40% cells expressing maC46.Early virus
replication kinetics were not accelerated by the addition of maC46-
expressing cells (data not shown). In conclusion, maC46-expressing
T cells are able to trap HIV-1 virions at the cell surface but do not
efficiently transfer virus to non-transduced neighboring T cells.
Figure 3. Preferential survival of cells expressing the maC46 fusion inhibitor following HIV-1 infection. A. Flow cytometric analysis for
expression of GFP and HIV-1 p24 Gag at the indicated times post-infection. Non-transduced CEMx174 cells were mixed with transduced cells
expressing the maC46 inhibitors such that approximately 25–30% of the cells were GFP
+. Mixtures of cells were then infected with HIV-1NL4-3 at a MOI
of 10
23 TCID50 per cell. Expression of HIV-1 p24 Gag and GFP were determined by flow cytometry on days 5, 9, 14 and 21. B. Survival advantage of
cells expressing maC46 following HIV-1 infection. Mixtures of non-transduced CEMx174 cells and transduced cells expressing the shI, maC46, and
antisense env inhibitors, or transduced with the HJ57 control vector (GFP) were generated such that approximately 25–30% of the cells were GFP
+.
Cells were then infected with HIV-1NL4-3 at MOI of 10
23 TCID50 per cell or remained uninfected. The percentage of GFP
+ cells in the absence of HIV-1
infection was stable for each vector examined over the 21 day culture period (data not shown). C. Mixtures of non-transduced CEMx174 cells and cells
transduced with vectors expressing either the sh(tat/rev), antisense env (VRX494), or the maC46 fusion inhibitors, were generated at the ratios
indicated at time 0 and then infected with HIV-1NL4-3 at an MOI of 10
23 TCID50/cell. Initial mixtures of vector-transduced CEMx174 cells ranged from
1% up to 95% GFP
+ cells. The percentage of GFP
+ cells was determined by flow cytometry at the indicated times post-infection.
doi:10.1371/journal.pone.0012357.g003
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lymphocytes following HIV-1 infection
We then analyzed if maC46 could also confer a selective
advantage to primary human T lymphocytes in HIV-1-infected
cultures. Primary human mononuclear cells were isolated,
depleted of CD8
+ T cells, prestimulated with anti-CD3 and anti-
CD28-coated beads, and then transduced with the maC46-GFP
vector M589 or the GFP control vector to a level of 80% and 57%
GFP
+ cells, respectively. On day 5 after transduction, cells were
diluted with non-transduced CD8-depleted T cells to generate a
transduction level of 10%. The cultures were challenged with the
dual-tropic primary HIV-1 isolate D117/II. Cells were analyzed
repeatedly by flow cytometry for CD4 and transgene (GFP)
expression (Figure 5). In uninfected control cultures, the
percentage of CD4
+ T cells remained high throughout the 31
days of observation, and only slightly declined to 86% in the
maC46 (M589) and 77% in the GFP control vector-transduced
cultures. In contrast, the percent of CD4
+ T cells declined
drastically in the HIV-infected cell cultures. Cultures transduced
with the control vector were completely deprived of CD4
+ T cells
by day 31 (Figure 5A). In the maC46-expressing, HIV-1-infected
culture, loss of CD4
+ T cells was much less pronounced, with the
level of CD4
+ T cells stabilizing at around 50% at day 20
(Figure 5A). The level of transgene-positive cells slowly declined in
the non-infected and in the infected, control-vector transduced
cultures. In contrast, the percentage of maC46-expressing cells
increased to nearly 100% within 20 days in the HIV-1-infected
cultures (Figure 5B). This accumulation of transduced cells was
accompanied by an increase in the transgene expression level as
measured by geometric mean fluorescence of GFP, which again
declined after the percentage of transgene-positive cells increased
after day 20, suggesting that the selective pressure of HIV-1
infection favored the survival of cells with high level transgene
expression (Figure 5C).
Positive selection of maC46-expressing primary human
CD4
+ T cells in a xenotransplant mouse model after HIV-1
infection
Finally, we studied the ability of maC46 to provide a selective
advantage in vivo in a human xenotransplant mouse model.
Human primary CD4
+ T cells were transduced with maC46
(M589) or the lentiviral GFP control vector, infected with
HIV-1D177/II, and transplanted into NOG (NOD SCID gam-
Figure 4. Adsorption of HIV-1 virions to the surface of transduced cells expressing maC46. A. Localization of virus in PM-1 cells
transduced with M589, which expresses maC46 and GFP, was analyzed by confocal microscopy. Mixtures of maC46-GFP transduced and non-
transduced cells (approximately 10% GFP
+) were infected with HIV-1D117/II. After 10 days, cells were stained for HIV-1 p24 (red) and analyzed for
expression of GFP (green). maC46-GFP
+ cells show p24 signal only on the cell membrane, whereas non-transduced cells have a cytoplasmic p24
staining. B. A3-CCR5 or A3-CCR5-maC46 cells were incubated with HIV-pseudotyped viral particles. After 5 hours cells were fixed, stained for p24, and
analyzed for the presence of bound viral particles. C. A3-CCR5 cells expressing maC46 were analyzed for their potential to transfer replication-
incompetent lentiviral particles pseudotyped with an HIV envelope to PM-1 cells. A3-CCR5 or A3-CCR5-maC46 cells were incubated with the viral
particles for 5 hours and after washing, transferred to PM-1 cells expressing RFP at a final ratio of 1:1. GFP expression of PM-1 cells was analyzed by
flow cytometry after 3 days.
doi:10.1371/journal.pone.0012357.g004
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2/2) mice. Human CD4, human CD45, and GFP expression
were monitored by flow cytometry. HIV-1 replication was
analyzed by a commercial RT-PCR-based assay in mouse serum.
When CD4
+ T cell counts were examined as a percentage of all
cells, CD4
+ T cell counts in the blood of uninfected animals
increased over time (Figure 6A), whereas in the HIV-1-infected
animals the percentage of CD4
+ T cells failed to expand in mice
transplanted with CD4
+ T cells expressing maC46 or in mice
transplanted with cells transduced with the control vector.
However, when the percentage of CD4
+ cells was expressed as a
percentage of human CD45
+ cells, we observed a marked
expansion of maC46-expressing cells from 18% up to 60% in
the infected group during the first 20 days after transplantation
(Figure 6B), while a stable level of transgene positive CD4
+ T cells
was seen in the uninfected mice and in the infected mice
transplanted with cells expressing the control vector. Thus, maC46
is also able to confer a selective advantage in this in vivo setting.
However, the percentage of maC46-expressing cells was not
sustained and the level of transgene-positive cells declined again
towards the end of follow-up. High levels of HIV-1 RNA of over
10
5 copies per ml were measured in mouse sera at day 14, but viral
loads decreased by 30 to 100-fold at day 34 (Figure 6C). No
significant difference in viral load was seen between the maC46-
and control vector treated groups, perhaps because sustained
regeneration of maC46-expressing cells was not achieved in this
xenograft model. At day 35, all mice developed severe xenogenic
graft versus host disease and had to be euthanized.
Discussion
The activity of three antiviral genes, an shRNA directed at tat/
rev, a long RNA antisense element, and a membrane-anchored
antiviral C peptide (maC46) were compared. All three transgene
products suppressed HIV-1 replication in cell culture. However,
only the membrane fusion inhibitor maC46 provided a strong
selective advantage to gene-modified cells in infected T cell lines.
Furthermore, maC46 led to the preferential survival of gene-
modified cells in primary CD4
+ T cells and in a xenotransplant
mouse model.
All three antiviral genes have been previously shown to have
potent antiviral activity, although the tat/rev-specific shRNA has
been shown to mediate more robust inhibition of HIV when used
in combination with other inhibitors [7,9–11,18,25]. In addition,
all of these inhibitors have all have been tested in clinical trials,
either alone (VRX494, maC46) or in combination with other
inhibitory genes (shI) [7,9,14,18,25]. Initially, we compared the
ability of the three transgenes to suppress HIV-1 replication at
different MOIs in cell lines, in which .95% of the cells were
Figure 5. In vitro selection of maC46-expressing primary human T cells. Human CD4
+ T cells were transduced with either a control lentiviral
vector expressing GFP alone (M420) or a vector expressing maC46 and GFP. On day 5 after transduction, cells were diluted with non-transduced cells
to achieve 10% GFP
+ cells, and the mixtures were infected with HIV-1D117/II. Data are presented as the mean 6 the standard error of the mean (SEM)
of triplicate samples. A. Flow cytometric analysis of the percentage of CD4
+ T cells as a percentage of all viable cells. Infected cultures (closed
symbols) showed a sustained loss of CD4
+ T cells. B. Preferential survival of maC46-expressing CD4
+ T cells following HIV-1 infection. C. Increased
expression of GFP on PM-1 cells transduced with the maC46-GFP vector (M589) after HIV-1-infection. The geometric mean of GFP expression (Geo
mean) on human CD4
+ T cells was analyzed at the indicated time points.
doi:10.1371/journal.pone.0012357.g005
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generally observed, especially early after infection. The most likely
reason for this phenomenon is that the virus must go through more
cycles of replication to infect all cells and reach saturation, the
factor of inhibition (IF) being a function of the number of cycles (n)
and the antiviral activity per cycle (i) (ideally IF=i
n). In
accordance with this prediction, the overall antiviral activity for
the shRNA inhibitor and the antisense RNA was most
pronounced at the lowest MOI. For the maC46 inhibitor, viral
replication was found to be nearly completely suppressed, even at
a high MOI. This is in accordance with the reported strong
antiviral potency of membrane-anchored C-peptides of more than
1000-fold per viral entry cycle [26]. A variety of other approaches
to inhibit HIV-1 entry have been developed, many of which target
the CCR5 coreceptor [8,27,28], and future direct comparative
studies with maC46 will be necessary to assess their relative
potency. Taken together, while all genes showed antiviral activity,
maC46 was most potent in this assay.
As noted above, the ability of an antiviral transgene to support
selection of gene-modified cells may have a significant impact on
its therapeutic activity, since only a small fraction of the estimated
more than 10
11 potential target cells for HIV-1 in a human subject
can be genetically modified. In the setting of preferentially loss of
unmodified CD4
+ T cells due to HIV-induced cell death,
expansion of CD4
+ T cells expressing an inhibitor able to mediate
a survival advantage could result in a repopulation of the immune
system by cells resistant to HIV-1 infection, as was observed in the
HIV-1-infected patient who underwent a bone marrow transplant
with hematopoietic cells deficient in CCR5 [21]. However, in
practice a number of factors may limit the ability of genetically-
modified cells to expand and restore immune function in vivo,
including the ongoing production of unmodified CD4
+ T cells
susceptible to HIV-1 infection, limitations in the proliferative
capacity of modified cells, indirect mechanisms of cell death, and
processes such as lymph node fibrosis that may affect the efficiency
of CD4
+ T cell reconstitution [29]. Although other mechanisms
mediated by genetic inhibitors may also mediate therapeutic
effects [12,30], we found that the antiviral potency of the analyzed
transgenes correlated with their ability to provide such a selective
advantage. In mixed HIV-1-infected cultures of gene-modified
and non-modified cells, only the maC46 expressing cells were able
to expand. Transgene expression and antiviral activity is often
Figure 6. Survival advantage of maC46-expressing human CD4
+ T cells in HIV-1-infected humanized mice. Human T cells were
transduced with a control vector (M420) expressing GFP alone (squares) or the M589 vector expressing maC46-GFP (circles) and then infected with
the HIV strain D117/II. Infected and uninfected cells were injected intraperitoneally into adult NOG mice. Four infected and 5 uninfected mice were
followed for 5 weeks for each vector. A. Relative numbers of human CD4
+ T cells. The percentage of human CD4
+ T cells as a fraction of total viable
cells was calculated. Means and the SEM for each group are shown. B. HIV infection leads to a selective survival of maC46-GFP expressing human
CD4
+ T cells (red closed circles) in vivo. Means and the SEM for each group are shown. C. Viral load in the serum of individual infected mice is not
altered by expression of maC46-GFP. Differences in viral loads between mice receiving CD4
+ T cells transduced with the maC46-expressing vector and
the GFP control vector were not significant (Mann-Whitney test).
doi:10.1371/journal.pone.0012357.g006
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level of maC46 on transduced primary T cells is consistently lower
than on transduced T cell lines [9]. However, here we show that
the level of transgene expression in primary human T cells is
sufficient to support selection and sustained maintenance of gene-
modified cells in in vitro cultures. Moreover, maC46-expressing
human CD4
+ T cells showed a preferential survival compared
with untransduced CD4
+ T cells after transplantation in HIV-1-
infected NOG mice. However, the accumulation was only
transient, the fraction of maC46-expressing cells declined towards
the end of the observation period, and no effect on viral load was
achieved. The observation that the maC46-expressing CD4
+ T
cells preferentially survived but did not proliferate and expand at
the rate seen in uninfected mice suggests that T cell regeneration
may be disturbed also for the uninfected, maC46-expressing CD4
+
T cells in the infected mice. Unfortunately, the study of potential
long-term effects of gene-therapeutic strategies on cell and virus
dynamics is limited in this mouse model by the manifestation of
xenogeneic graft versus host disease around week five after
transplantation.
Despite the strong selective advantage conferred by maC46
found in this study, no significant accumulation of gene-modified
peripheral CD4
+ T cells was observed in a previous clinical trial in
10 HIV-1-infected patients that had failed HAART treatment
[18]. Possibly, similar mechanisms counteracted the expansion of
gene-protected cells in the presence of ongoing virus replication in
the mouse experiment described here. These data show that a
major challenge in gene therapy for HIV infection is to promote
regeneration and expansion of the gene-protected CD4
+ T cells
under the selective pressure of ongoing virus replication, a hostile
environment for T cell regeneration. Taken together, this study
demonstrates the strong antiviral efficacy of maC46 as well as its
ability to mediate a survival advantage in vitro and in vivo. Analysis
of the ability of genetic inhibitors to mediate a survival advantage
provides distinctive information not provided by standard
inhibition assays and may offer information relevant to the in vivo
efficacy of these genetic inhibitors.
Materials and Methods
Ethics statement
Animal experiments were performed in compliance with the
local animal experimentation guidelines and approved by the
regional council (Regierungspra ¨sidium, Darmstadt, Germany,
Protocol #F123/35). Human PBMCs were obtained from normal
anonymous donors, who provided written informed consent under
protocols approved by the Ethics Committee of the Medical
Faculty of the Johann-Wolfgang Goethe University Frankfurt,
Protocol #81/10.
Cell culture
The cell lines CEMx174 (ATCC) and T2-SEAP cells (kindly
provided by Welkin Johnson, NEPRC, HMS) were cultured in
RPMI-1640 (Invitrogen, Carlsbad, CA) plus 20% fetal bovine
serum (FBS, HyClone, Logan, UT), 10 mM HEPES, 50 U/ml
penicillin and 50 mg/ml streptomycin (Cellgro, Mediatech,
Manassas, VA), 2 mM L-glutamine (R20 medium) at 37uC with
5% CO2. The human embryonic kidney cell line 293T and the
human osteosarcoma cell line U20S were cultured in DMEM
(Invitrogen) plus 10% FBS, 50 U/ml penicillin and 50 mg/ml
streptomycin, 2 mM L-glutamine (D10 medium) at 37uC with 5%
CO2. The cell line PM-1 (obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH from Drs. Paulo Lusso and Robert Gallo) was
cultured in RPMI 1640 supplemented with 5% fetal bovine serum,
2% L-glutamine and 1% penicillin/streptomycin and the cell lines
A3.01-CCR5 (EU Programme EVA Centre for AIDS Reagents)
in RPMI 1640 with 5% fetal bovine serum, 2% L-glutamine, 1%
penicillin/streptomycin and 1 mg/ml G418 (Roth, Karlsruhe,
Germany).
Human low-density mononuclear cells were obtained from
normal anonymous donors, and were isolated by density gradient
centrifugation (Pancoll, PAN, Aidenbach, Germany), treated with
0.45% ammonium chloride to lyse red blood cells and washed
with PBS. CD8
+ cells were depleted using CD8-specific microbe-
ads (Miltenyi Biotec, Bergisch Gladbach, Germany). PBMCs were
stimulated with Dynabead CD3/CD28 T cell expanders (Dyna-
beads CD3/CD28, Invitrogen Dynal, Eggenstein, Germany) and
cultured in X-Vivo 15 with 5% human serum, 2% L-glutamine,
1% penicillin/streptomycin, 20 mM HEPES and recombinant
human IL-2 (100 U/ml, Proleukin, Novartis, Berne Switzerland)
at 37uC with 5% CO2.
Lentiviral vectors
The construct maC46 (M589) was generated using a three step
PCR. For the first PCR reaction, the maC46 transgene cassette
was amplified from M87o-RRE [9] using the oligonucleotides
M87o-for (59 GGG GGA TCC CCC GGG CTG CAG GAA
TTC GCC CTT CTC TAG CGC TAC CGG TCG CCG C 39)
and M87o-rev (59 TCC TCG CCC TTG CTC ACC ATG CAT
GCG GGC TCC AGC TCC AGG CGC T 39). In a second PCR
reaction, the GFP sequence was amplified from pHR9SIN.cPPT-
SEW [31] (M420) using the oligonucleotides GFP-for (59 GCC
CGC ATG CAT GGT GAG CAA GGG CGA GGA G 39) and
GFP-rev (59 CTA CTA GAT ATC GAA TTC ACA TGT GGT
GGT GGT GGT GG 39). Finally, the two PCR products were
used in a third PCR to create a cassette containing maC46 fused to
GFP. This PCR product was digested with EcoRV and BamHI.
pHR9SIN.cPPT-SEW was digested with SbfI, the 39 overhang
was removed, and the vector was further digested with BamHI to
remove the GFP transgene and finally ligated with the maC46-
GFP cassette.
Virions for the lentiviral vector VRX494 [32] were generated at
VIRxSYS (Gaithersburg, MD) by transient transfection of 293T
cells with the transfer vector and a plasmid that expresses Gag-Pol,
Tat, Rev and VSV-G as previously described [25]. Dilutions of
viral stock were used to transduce HeLa-Tat cells and the
percentage of GFP positive cells was determined by flow
cytometry. Stock titers ranged from 2.8610
9 to 4610
9 transducing
units (TU) per ml.
Virions for the lentiviral vectors HJ57, pHIV-shI-GFP [10,11],
M420 (GFP lentiviral control used for PBMC and mouse
experiments) and maC46(M589) were generated by transient
transfection of 293T cells in a five plasmid system with the transfer
vector and separate plasmids that expresses Gag-Pol (pHDM-
Hgpm2), Tat (pHDM-tat1b), Rev (pRC-CMV rev1B) and VSV-G
(pHDM VSV-G) or in a three plasmid system with the transfer
vector and separate plasmids that express Gag-Pol, Tat and Rev
(pCMV-dR8.91 [33]) and VSV-G (pHCMV-VSV-G [34]) in D10
medium supplemented with sodium benzoate. Replication-defi-
cient HIV-1 vector particles expressing GFP were produced by
transient transfection of 293T cells using plasmids that express
GFP (M420), Gag Pol, Tat and Rev (pCMV-dR8.91) and JRFL
HIV-1 envelope [35]. Supernatants were clarified by filtration,
and virions were concentrated by ultrafiltration. Virus stocks were
analyzed for HIV p24 Gag by ELISA (Coulter HIV-1 Core
Antigen Assay, Coulter International Corp., Miami, FL; or
Advanced BioScience Laboratories, Inc., Kensington, MD)
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stock were used to transduce CEMx174 cells or U20S cells or PM-
1 cells and the percentage of GFP positive cells was determined by
flow cytometry. Stock titers were generally around 10
7 per ml.
Transductions
CEMx174 cells were transduced with the lentiviral vectors
HJ57, pHIV-shI-GFP, and M589 at MOIs of 0.5 IU per cell in
R20 medium plus 8 mg/ml polybrene (Sigma) during 30 min
spinoculation (2000 rpm) and subsequent overnight culture at
37uC with 5% CO2. After 24 hours, the cells were washed and
expanded in R20 media. The CEMx174-VRX494 cells were
transduced as previously described [36]. Human PBMC were
isolated via density gradient centrifugation (Pancoll, PAN,
Aidenbach, Germany) and CD8-depleted using human CD8
microbeads (Miltenyi Biotec). Primary human T lymphocytes
(5610
6 cells per 6-well in 5 ml medium) were transduced with
M589 or M420 at MOI of 3 and stimulated with beads
(Dynabeads CD3/CD28, Invitrogen Dynal, Eggenstein, Ger-
many). After 3 days cells were washed with medium, reseeded in
fresh medium (1610
6 cells/ml) and further cultivated for 2 days.
On day 5 magnetic, beads were removed, cells were diluted with
non-transduced cells to attain a final concentration of 10% GFP
+
cells and used for experiments.
Vector-transduced CD4
+ T cells were analyzed for the presence
of replication-competent lentivirus by incubating supernatant from
transduced cells with T2-SEAP cells, which have Tat-dependent
expression of secreted embryonic alkaline phosphate (SEAP).
Three-five days later, SEAP expression in cell-free supernatant
was measured using the Phospha-light system (Tropix, Applied
Biosystems, Foster City, CA). Based on experiments with HIV-
1NL4-3, this assay has a lower limit of detection of 50 infectious
particles per ml. All assays for replication-competent lentivirus
were negative.
Flow cytometric analysis
Transduced populations of CEMx174 cells were analyzed for
the percentage of GFP expression in each population by flow
cytometry using a FACSCalibur (BD BioSciences, San Jose, CA).
GFP expression was measured in the FITC channel. Transduced
populations of CEMx174 cells (GFP
+ cells) were sorted to greater
than 95% GFP
+ using a BD FACS Vantage. PBMCs were
resuspended in PBS with 1% FCS and 0.05% sodium azide (FACS
buffer) and stained by incubation with human-specific PerCP-
conjugated anti-human CD4 antibodies (clone SK3, BD-Phar-
Mingen, Heidelberg, Germany) for 15 minutes at room temper-
ature. Cells were analyzed by flow cytometry using a FACSCa-
libur.
Expression of GFP and intracellular expression of HIV-1 p24
Gag was determined in transduced and infected CEMx174 and
PM-1 populations using Perm & Fix reagents (Caltag Laborato-
ries, Burlingame, CA) and staining with a PE-conjugated HIV p24
Gag antibody [37] (Clone KC57, Beckman Coulter, Brea, CA).
The cells were washed and analyzed for expression of GFP and
HIV-1 Gag by flow cytometry using a FACSCalibur.
To analyze transgene expression in the different cell populations
in vivo approximately 50 ml blood or splenocytes of transplanted
mice were incubated with 1 mg of a monoclonal antibody to mouse
Fc-receptors (2.4G2, Bio Express, West Lebanon, NH) for 15
minutes at room temperature. Cells were stained with PerCP-
conjugated anti-human CD4 antibodies (clone SK3, BD-Phar-
Mingen) and APC-conjugated anti-human CD45 antibodies (clone
HI30, BD-PharMingen) for 15 minutes at room temperature.
Erythrocytes were lysed using lysing buffer (BD PharmLyse). Cells
were washed and analyzed using a FACSCalibur.
Viral replication assays
HIV-1NL4-3 viral stocks (kindly provided by Ronald C.
Desrosiers, NEPRC, HMS) were generated by infection of
CEMx174 cells and harvesting cell free supernatants on day 8–
12 after infection. Viral production was analyzed by ELISA for
HIV-1 p24 Gag (as described above) and/or titered for TCID50
by limiting dilution assay targeting T2-SEAP cells with slight
modifications [38]. HIV-1D117/II is a highly cytopathic dual-
tropic primary isolate generated at the Georg-Speyer-Haus (von
Briesen, unpublished data), which was used for the experiments
in primary T cells, as it readily replicates in PBMC. HIVD117/II
viral stocks were generated by infection of human PBMC. Cells
were passaged for 1–2 weeks and cell free supernatants were
harvested. Viral stocks were titrated on TZM-bl cells as described
previously [39]. Vector-transduced and untransduced CEMx174
cells and mixed populations of vector-transduced and non-
transduced CEMx174 cells were resuspended in viral supernatant
at MOIs of 0.0001 to 0.01 TCID50/cell of HIV-1NL4-3 for
4 hours, before washing and initiating cultures in 10–20 ml R20
media. Viral replication was assessed by measuring p24 Gag
production in cell-free supernatant with ELISA as described
above. The percentage of GFP
+ and/or HIV-1 p24 Gag
+ cells
was analyzed by flow cytometry.
For primary human T lymphocytes cells were transduced as
described above, and on day 5 after transduction, cells were
infected with HIVD117/II. After 16 hours cells were washed with
PBS and reseeded in fresh medium in 24 well plates (5610
5 cells
per well). Every 2–3 days, cells were split and fresh medium with
100 U IL-2/ml was added.
Localization of p24 via confocal microscopy
Mixed populations of maC46-GFP and native PM-1 cells were
infected with HIV-1D117/II. Cells were stained intracellularly for
p24 antigen (see above). Cells were spun on cover slips using a
cytospin (Tharmac CellSpin II, Tharmac, Waldsolms, Germany).
The cover slips were fixed on the microscope slide using mounting
medium (ProLong Gold antifade reagent, Molecular Probes-
Invitrogen, Karlsruhe, Germany) and then analyzed with a
confocal microscope (Leica TCS SL with Leica LCS-Software,
Leica Microsystems, Wetzlar, Germany) for p24 and GFP
localization.
Virus replication assays in xenotransplanted NOG mice
NOD/SCID/gamma chain knockout mice (NOD.Cg-Prkdcsci-
dIl2rgtm1WjL/SzJ) were obtained from Charles River laborato-
ries (Sulzfeld, Germany). Mice were bred and maintained under
specific pathogen free conditions in individually ventilated cages in
the animal facilities of the Georg-Speyer-Haus. The experiments
were performed in compliance with the local animal experimen-
tation guidelines. On day 5 after transduction, human T
lymphocytes were infected with HIVD117/II. After 16 hours cells
were harvested, washed with PBS and transplanted into adult
NOG mice via intraperitoneal injection. Blood of the transplanted
mice was regularly collected from the tail vein. Viral load in the
serum of the infected mice was determined by RT-PCR (AmpliPre
Cobas Taqman, Roche, Basel, Switzerland). Mice were eutha-
nized after anesthesia by cervical dislocation as soon as they
showed signs of severe graft versus host disease.
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Statistical analysis were done using GraphPad Prism software
(GraphPad Software, Inc., La Jolla, CA).
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